THERAPEUTISCHE OLIGONUKLEOTIDE

European patent · EP3329004 · In force

Register entry

Publication number
EP3329004
Application number
EP16750690
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jul 29, 2016
Published
Jun 6, 2018
Granted
Jan 15, 2020
Protection ends at the latest
Jul 28, 2036
Next annual fee due
Jul 31, 2027
IPC classes
C12N 15/113 (2010.01)
A61K 31/7088 (2006.01)
Priority
WO PCT/EP2015/178809 29.07.2015
PCT application
PCT/EP2016/068162 29.07.2016
PCT publication
WO2017/017253 02.02.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.07.2026 → 31.07.2027

    Published in Swissreg on 01.08.2026

  2. Aug 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.07.2025 → 31.07.2026

    Published in Swissreg on 01.08.2025

  3. Aug 1, 2024

    Change

    Published in Swissreg on 01.08.2024

  4. Aug 1, 2023

    Change

    Published in Swissreg on 01.08.2023

  5. Aug 1, 2022

    Change

    Published in Swissreg on 01.08.2022

  6. Mar 25, 2020

    Agent entered

    Representative
    Dennemeyer AG, Bahnhofstrasse 23, 6300 Zug

    Published in Swissreg on 25.03.2020

  7. Jan 15, 2020

    Granted

    Published in Swissreg on 15.01.2020

Parties

Holder

IFOM Fondazione Istituto Firc di Oncologia Molecolare

Via Adamello 16, 20139 Milano, IT

Agent

Dennemeyer AG

Bahnhofstrasse 23, 6300 Zug

Inventor

ROSSIELLO, Francesca

20139 Milano, IT

AGUADO, Julio

20139 Milano, IT

D'ADDA DI FAGAGNA, Fabrizio

20139 Milano, IT

JONES-WEINERT, Corey

20139 Milano, IT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.